A Canadian cannabis company last month received Health Canada approval to include psilocybin, psilocin, and cocaine in its substance dealer’s license.
Adastra Holdings Ltd. said the amendments to its license allow the company to “possess produce, sell and distribute up to 1,000 grams of psilocybin and psilocin” and “interact with up to 250 grams of cocaine.” The amendment also allows the company to import coca leaves to manufacture and synthesize cocaine.
In a statement, Michael Forbes, CEO of Adastra, said the company “proactively pursued” the amendment to add cocaine to the license last December.
“Harm reduction is a critically important and mainstream topic, and we are staying at the forefront of drug regulations across the board. … We will evaluate how the commercialization of this substance fits in with our business model at Adastra in an effort to position ourselves to support the demand for a safe supply of cocaine.” — Forbes in a statement
The company’s amendment comes less than a year before drug reforms are set to take effect in British Columbia at the end of the year. Under the plan, there will be a three-year exemption under the nation’s Controlled Drugs and Substances Act for adults 18 years and older to possess up to 2.5 grams of opioids, cocaine, methamphetamine, MDMA, or some combination thereof.
Get daily cannabis business news updates. Subscribe